Search
Contact
exPDite-2
exPDite-2 is a phase 3 study evaluating the potential efficacy and safety of a 1-time investigational cell therapy on movement, balance, motor symptoms, and quality of life in adults with Parkinson’s disease.
When implanted into your brain in a 1-time surgery, the study drug may replace dopaminergic neurons lost from Parkinson’s disease, with the aim of integrating into the brain to produce dopamine.
What to Expect
Participating in exPDite-2 includes a screening phase, a 1-time surgery, ongoing monitoring, and long-term follow-up with the study team. You may receive the study medicine or a simulated surgery. We understand that participating in a study is a big decision. Talk with your family, doctors, or others who suffer from Parkinson’s disease.
You May be Able to Participate If You…
• were diagnosed with Parkinson’s disease 4–12 years ago.
• are 45–75 years old.
• are taking levodopa-based treatment to control motor symptoms.
• have at least 2.5 hours of OFF time each day.
The study doctors will explain all the requirements to you. Being in a clinical study is voluntary and you can leave the study at any time. There are study centers across the United States, Australia, and Canada; and you can remain connected with your own doctor throughout the study.
For qualified exPDite-2 study participants, all treatments and tests may be provided at no charge. Support with travel associated with the study and reasonable reimbursement costs for you and your care partner may be provided throughout the exPDite-2 study.
Find out more about the study details and how you can participate here.